Want to see AU:PYC full AI Analyst Report?
Top Page
PYC Therapeutics Limited
(Sydney:PYC)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$1.50
â–¼(-27.88% Downside)
Action:Reiterated
Date:10/27/26
The score is held down primarily by weak financial performance—ongoing losses, negative cash flow, and a FY2026 revenue drop to zero—despite a comparatively strong, low-debt balance sheet. Technicals add pressure with bearish momentum signals, while valuation is constrained by negative earnings (negative P/E) and no dividend support.
Positive Factors
Low Leverage
Minimal debt relative to equity gives PYC a stronger solvency base than a highly leveraged development biotech. This reduces balance-sheet pressure while the company funds its pipeline, although it does not yet solve the lack of profitability.
Negative Factors
Persistent Operating Losses
Persistent large losses show that PYC has not yet converted its research and development activities into a profitable operating model. Continued losses can constrain internally funded growth and make future value creation dependent on successful clinical and commercial execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Minimal debt relative to equity gives PYC a stronger solvency base than a highly leveraged development biotech. This reduces balance-sheet pressure while the company funds its pipeline, although it does not yet solve the lack of profitability.
Read all positive factors
PYC Therapeutics Limited (PYC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$1.85B
Dividend YieldN/A
Average Volume (3M)4.92M
Price to Earnings (P/E)―
Beta (1Y)1.53
Revenue GrowthN/A
EPS Growth39.63%
CountryAU
Employees37
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding984,750,400
10 Day Avg. Volume2,935,692
30 Day Avg. Volume4,924,293
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-27.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.90Price Target Upside87.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.08
Revenue Forecast (FY)N/A
PYC Therapeutics Limited Business Overview & Revenue Model
Company Description
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical tr...
PYC Therapeutics Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 23.49M | 22.06M | 15.81M | 16.04M |
| Gross Profit | -1.20M | 23.49M | 22.06M | 14.92M | 15.20M |
| EBITDA | -81.47M | -52.51M | -54.55M | -38.25M | -29.39M |
| Net Income | -43.34M | -50.30M | -37.73M | -22.79M | -13.86M |
Balance Sheet | |||||
| Total Assets | 708.52M | 183.28M | 91.24M | 37.17M | 45.35M |
| Cash, Cash Equivalents and Short-Term Investments | 447.56M | 153.05M | 66.87M | 15.57M | 29.11M |
| Total Debt | 624.99K | 1.02M | 1.11M | 315.49K | 943.77K |
| Total Liabilities | 15.18M | 13.27M | 10.18M | 8.72M | 5.15M |
| Stockholders Equity | 693.33M | 169.57M | 80.50M | 27.75M | 39.35M |
Cash Flow | |||||
| Free Cash Flow | -45.05M | -52.54M | -38.90M | -24.91M | -22.17M |
| Operating Cash Flow | -44.52M | -51.56M | -38.59M | -24.42M | -21.78M |
| Investing Cash Flow | -616.16M | -975.40K | -307.04K | -477.12K | 32.68M |
| Financing Cash Flow | 563.22M | 138.66M | 90.19M | 11.44M | -182.36K |
PYC Therapeutics Limited Technical Analysis
Negative
2.08
Price Trends
2.31
Negative
2.02
Negative
1.69
Positive
Market Momentum
-0.15
Positive
38.91
Neutral
75.25
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PYC, the sentiment is Negative. The current price of 2.08 is above the 20-day moving average (MA) of 2.07, below the 50-day MA of 2.31, and above the 200-day MA of 1.69, indicating a neutral trend. The MACD of -0.15 indicates Positive momentum. The RSI at 38.91 is Neutral, neither overbought nor oversold. The STOCH value of 75.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PYC.
PYC Therapeutics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | AU$2.58B | 128.62 | 6.03% | 0.74% | -68.00% | -86.31% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$110.10M | -6.95 | 84.67% | ― | ― | 42.51% | |
44 Neutral | AU$1.85B | -31.81 | -10.31% | ― | ― | 39.63% | |
43 Neutral | AU$217.31M | -26.32 | -42.35% | ― | 145.32% | 25.75% | |
42 Neutral | AU$585.74M | -5.41 | -51.15% | ― | ― | -44.83% |
* Healthcare Sector Average
AU:PYC
PYC Therapeutics Limited
1.88
0.65
52.85%
AU:NEU
Neuren Pharmaceuticals Limited
20.36
-1.24
-5.75%
AU:SPL
Starpharma Holdings Limited
0.45
0.12
35.14%
AU:CU6
Clarity Pharmaceuticals Ltd.
1.57
-3.33
-67.96%
AU:RCE
Recce Pharmaceuticals Ltd.
0.36
-0.07
-15.29%
PYC Therapeutics Limited Corporate Events
PYC Therapeutics Showcases Early PKD Trial Data for PYC-003 at ASN Meeting
Oct 22, 2026
PYC Therapeutics announced that Dr. Jagadeesh Kurtkoti will present safety and exploratory efficacy data from the Phase 1a single ascending dose study of its drug candidate PYC-003 in patients with polycystic kidney disease. The presentation will ...
PYC Therapeutics Confirms Lapse of 100,000 Options
Oct 8, 2026
PYC Therapeutics Limited has announced the cessation of 100,000 PYCAZ options, which were due to expire in May 2028 with an exercise price of $1.70, after the conditional rights attached to these securities lapsed because the required conditions w...
PYC to unveil early efficacy signals for PKD drug PYC-003 at ASN
Oct 6, 2026
PYC Therapeutics will present exploratory efficacy data for its Polycystic Kidney Disease candidate PYC-003 at the American Society of Nephrology conference later this month. The early-stage results come from Phase 1a/1b trials in which PKD patien...
PYC to Unveil New RP11 Trial Data for VP-001 at Euretina 2026
Oct 1, 2026
PYC Therapeutics announced that new data from its clinical-stage drug candidate VP-001, developed to treat Retinitis Pigmentosa type 11, will be presented at the Euretina Congress in Vienna. The therapy targets the underlying genetic cause of RP11...
Index Rebalance Adds PYC Therapeutics to S&P/ASX 300
Sep 4, 2026
SP Dow Jones Indices has announced its September 2026 quarterly rebalance of the SP/ASX index series, bringing several changes across the SP/ASX 50, 100, 200 and 300 benchmarks while leaving the SP/ASX 20 unchanged. Among the additions, PYC Therap...
PYC Therapeutics Updates Investors, Emphasizes Early-Stage Status and Risks
Sep 3, 2026
PYC Therapeutics has released an investor presentation outlining an update on its business and drug development pipeline, emphasizing that the materials are a corporate communication aid and should be read alongside its past and future market anno...
PYC Therapeutics to Showcase ADOA Drug Data at NOSA 2026
Sep 2, 2026
PYC Therapeutics Limited, a clinical-stage biotechnology company listed on the ASX, specializes in precision RNA therapies for monogenic genetic diseases with no existing treatments and employs a proprietary delivery platform to boost drug potency...
Retail Employees Super Fund Exits Substantial Holding in PYC Therapeutics
Sep 2, 2026
Retail Employees Superannuation Pty Ltd, acting as trustee of the Retail Employee Superannuation Trust, has disclosed that it ceased to be a substantial shareholder in PYC Therapeutics Ltd as of 31 August 2026. The change followed a series of shar...
PYC Therapeutics Reports Positive Early Safety Data for PKD Drug PYC-003
Aug 30, 2026
PYC Therapeutics Limited is a precision medicine biotech focused on genetic diseases with no existing treatments, operating clinical-stage programs in Australia and the U.S. Its lead renal candidate, PYC-003, targets the underlying cause of Polycy...
PYC details evolving governance framework aligned with ASX principles
Aug 28, 2026
PYC Therapeutics has detailed its corporate governance framework for the 12 months to 30 June 2026, confirming adoption of the ASX Corporate Governance Council’s latest principles where appropriate for its size and operations. The board has ...
PYC Therapeutics Files 2026 Corporate Governance Statement with ASX
Aug 28, 2026
PYC Therapeutics Limited is an Australia-listed biotechnology company that discloses its governance and investor information via its website, in line with ASX regulatory requirements. The company’s operations are framed by the ASX Corporate ...
PYC Therapeutics Details Governance and Operations in 2026 Annual Report
Aug 28, 2026
PYC Therapeutics released its 2026 Annual Report, outlining its current corporate structure, including a board led by Chairperson Peter Coleman and CEO Dr Rohan Hockings, and detailing its registered office, principal place of business, and share ...
PYC Therapeutics Narrows Loss and Strengthens Balance Sheet in FY2026
Aug 28, 2026
PYC Therapeutics has lodged its preliminary financial report for the year ended 30 June 2026, showing income from ordinary activities rising 51.6% to $39.7 million while the net loss after tax narrowed 13.8% to $43.3 million. The company reported ...
PYC Therapeutics Schedules September Investor Webinar to Detail Pipeline Progress
Aug 17, 2026
PYC Therapeutics will host an investor webinar on 4 September 2026 to brief shareholders on progress across its pipeline of investigational RNA-based drug candidates during calendar year 2026. The event, held in Perth with an online option, unders...
PYC Therapeutics boosts CEO equity incentives with major option and rights grants
Aug 14, 2026
PYC Therapeutics has updated the market on changes to Chief Executive Dr Rohan Hockings’ interests, following the issue of a substantial package of unquoted options under the company’s long term incentive plan. The new options, expirin...
PYC Therapeutics advances genetic disease pipeline and strengthens corporate footing
Jul 28, 2026
PYC advanced its polycystic kidney disease program into a Phase 1b multiple ascending dose study in patients, after safety review approval for repeat dosing, and subsequently secured clearance to escalate to a higher dose cohort and to run an open...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.